Prezista darunavir: Phase IIIb data

In the open-label Phase IIIb ODIN trial in 590 treatment-experienced HIV patients, 800 mg once-daily Prezista plus 100 mg Norvir ritonavir met the primary endpoint of non-inferiority to 600 mg twice-...